Latigo Biotherapeutics, Inc. Common Stock (LTGO) — Working Capital to Net Assets Ratio
Latigo Biotherapeutics, Inc. Common Stock (LTGO) has a Working Capital to Net Assets ratio of -2.8% as of June 2026. Working capital of $7.62 Million (current assets of $59.20 Million minus current liabilities of $51.58 Million) is measured against net assets of $-276.08 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Latigo Biotherapeutics, Inc. Common Stock Working Capital to Net Assets (2024–2025)
This chart shows how Latigo Biotherapeutics, Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 2 annual periods from 2024 to 2025. As of June 2026, the ratio stands at -2.8%, reflecting working capital of $7.62 Million against net assets of $-276.08 Million USD. Read LTGO total liabilities for a breakdown of total debt and financial obligations.
Annual Working Capital to Net Assets for Latigo Biotherapeutics, Inc. Common Stock (2024–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Latigo Biotherapeutics, Inc. Common Stock from 2024 to 2025, covering 2 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Latigo Biotherapeutics, Inc. Common Stoc total assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -23.9% | $55.38 Million | $-231.67 Million | $73.83 Million | $18.45 Million | ▼ -18.7 pp |
| 2024 | -5.2% | $6.73 Million | $-129.60 Million | $21.16 Million | $14.44 Million | — |